Latest News

 Filter by Provider

Opus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investor panel featuring Chief Executive Officer Dr. George Magrath and Chief Financia

Monument Traders Alliance strategists detail a volatility-trading sleeve using IWM, QQQ and GLD options alongside longer-term holdings in Agnico Eagle Mines and Nuveen Municipal Value Fund for income.

The market has crashed before, and it'll probably happen again. So it's best to have a plan ready.

Tilray's transformation is still ongoing, but it just reached a critical milestone.

Musk just provided a mind-boggling 2027 revenue forecast for Space Exploration Technologies.

Netflix wants to claw back market share from YouTube, which has made considerable gains.

The earnings report and call were short on razzmatazz but long on substance, strengthening the investment case for the stock.

Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

Deep Fission (NASDAQ:FISN) outlined its development, regulatory and financing plans for underground nuclear power projects during its October 2026 business update, targeting initial commercial power from a pilot project in Parsons, Kansas, by December 2027 and broader deployments beginning in 2028.

The company's third quarter was marked by double-digit growth.

Forecasts point to a high likelihood of continued gains, but possible headwinds could interrupt growth.

If things seem too perfect on Wall Street, they probably are.

For its stock to take off, Samsara must transform customer value into profitable growth.

The conglomerate bought back its shares in June for around $488 each. Are they still a buy at a record?

You might be able to turn that $10,000 into $115,347 -- or more. (Or less.)

The power of dollars compounding over 20 years can turn a small dividend income into a huge one.

Investing in just this one exchange-traded fund (ETF) for the past 25 years could have set you up for serious financial security.

The stock has been on a great run this year.

Adagene (NASDAQ:ADAG) is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant investigator-sponsored trial in Singapore, Chief Strategy Officer Mickael Chane-Du said during a Chardan conferen

Bloom Energy has benefited from tailwinds from data centers for power solutions. Here's what the company must do to continue delivering for investors.

Exceeding expectations on the bottom line can't compensate for this shortcoming -- at least in some investors' eyes.

Many AI stocks beat the Nasdaq Composite this year, and these three picks look like they can repeat the feat in 2027.

Earnings jumped 22% last fiscal year. Why would I still want the stock around 12% cheaper?

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Annaly and AGNC are getting hit by rising rates; is that an opportunity for investors or a valid recognition of risk?

Just because you can multiply daily moves, doesn't mean you should.

The shocking part is that the gift is only a drop in the bucket compared to the founder's total wealth.

You don't have to wait until December to find out how much your Social Security check will grow.

Both stocks have soared in recent years.

Both of these biotech stocks could be appealing to income investors.

The AI software specialist is nearing a $10 billion year. Will its share price rise with its sales?

Amazon's stock popped after reporting strong AWS growth in Q2. I like the odds of history repeating.

Statistically speaking, tariffs have been bad news for Wall Street and consumers.

One class has a vote. Is that vote worth paying about 1% more for?

SpaceX’s AI business is booming. That has important implications for the broader industry.

There's a downside to a generous raise.

A bear market could be on the way, but the right strategy can protect your portfolio.

Capstone Energy+ (NASDAQ:CEPL) is positioning its distributed energy technology as a way to provide “energy certainty” for customers facing grid constraints, permitting delays and growing power needs, President and CEO Vince Canino said during a company presentation. Canino said businesses historic

Wealth and Trust fees surged 30% year-over-year as core EPS grew 25%.

Centrus Energy is the lone publicly traded U.S.-based uranium enricher.

Both automakers offer something different for potential investors.

It doesn't take huge sums of money to build a seven-figure investment portfolio.

Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said during a Chardan investor session. Korenberg said the company has expanded from deve

Altria is typically an income play, but the cigarette giant has shown some growth characteristics this year.

Did the fund that beat the hedge funds keep that up after the bet was over?

There are hundreds of billions at stake and fears that AI spending is creating an unsustainable bubble.

OmniAb (NASDAQ:OABI) Chief Financial Officer Kurt Gustafson outlined the company’s antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and biotechnology companies rather than develop

Shares of Meta have dropped nearly 10% this week.

Property casualty insurer Cincinnati Financial (NASDAQ:CINF) will be announcing earnings results this Monday after market hours. Here’s what to look for. Cin...

Home appliances manufacturer Whirlpool (NYSE:WHR) will be reporting earnings this Monday after market close. Here’s what investors should know. Whirlpool mis...